When injections fit into the hip OA pathway

For many people with hip osteoarthritis, the question arrives at a specific moment: is an injection worth trying before committing to surgery? The short answer is yes — for the right person, at the right stage — but only when it sits inside a broader plan rather than replacing one.

Conservative care comes first. Physiotherapy, targeted load management, and where appropriate, weight optimisation form the foundation of hip OA management. Injections work as a support layer on top of that foundation, not as a substitute for it.

The evidence base is strongest for what clinicians loosely describe as early-to-mid stage disease — joints that remain symptomatic despite conservative care but have not yet reached the end-stage structural failure that makes replacement the only realistic option. Most published trials draw their participants from this range, so the data that guides clinical decisions reflects this group.

One point applies to every injectable option: because the hip is a deep ball-and-socket joint, accurate placement cannot be confirmed by landmark alone. Image guidance — ultrasound or fluoroscopy — is a standard-of-care requirement, not an optional upgrade.

It is also worth setting expectations clearly from the outset. Hip OA injection trials consistently record a meaningful placebo response, which complicates how results should be interpreted. More importantly, no injection currently available has been shown to slow or reverse the underlying disease process. The goal is symptom control and preserved function — and, for many patients, buying meaningful time before a surgical decision becomes necessary.

Corticosteroid injections: the clearest short-term signal

Of all the injectables studied for hip osteoarthritis, corticosteroids carry the most consistent evidence and the widest guideline endorsement. A 2024 Bayesian network meta-analysis published in the Bone & Joint Journal, drawing on 16 randomised controlled trials and 1,735 participants, confirmed that steroid injection is significantly superior to placebo for both pain and function at three months — the sharpest head-to-head signal in the hip OA injection literature to date. NHS Cheshire & Merseyside's 2024 clinical policy, broadly reflecting EULAR and ACR-aligned guidance, strongly recommends intra-articular glucocorticoid injection for hip OA, and it remains the default injection choice in most UK musculoskeletal services.

Three months matters as a benchmark because that is where the evidence is most robust. By six months, the same meta-analysis found no significant advantage over placebo — corticosteroid is an effective short-term option, not a long-duration one.

Frequency carries its own constraints. Repeated injections are associated with potential chondrotoxic effects on articular cartilage, so they are not simply 'more of a good thing'. Clinicians typically limit use accordingly.

One practical point is worth flagging early: a minimum three-month gap between a hip injection and any planned arthroplasty is required to reduce perioperative infection risk. For patients who may be moving towards a surgical discussion, that timing should be raised with their care team sooner rather than later. Common formulations — triamcinolone, betamethasone, or methylprednisolone, usually combined with a local anaesthetic — are well-established, low-cost, and carry a low overall complication rate when appropriately administered.

Hyaluronic acid: where guidelines and clinical practice diverge

NICE guidance does not recommend hyaluronic acid (HA) for hip OA — yet it remains in clinical use, and the evidence picture is more nuanced than that headline suggests.

The gap between guideline caution and clinical practice is genuine and unresolved. Several published studies support HA's use in moderate-grade disease, particularly with high-molecular-weight formulations. The Qvistgaard 2006 three-arm RCT compared HA against corticosteroid and saline for hip OA; De Lucia et al.'s 2019 retrospective cohort found that repeated courses of high-molecular-weight HA were effective and well-tolerated in symptomatic hip OA, with high-MW products outperforming medium-MW formulations. Single-injection high-MW preparations are used in practice, and repeat dosing at approximately six-month intervals is feasible.

The 2024 Bayesian network meta-analysis in the Bone & Joint Journal adds a distinct data point: HA combined with PRP was the strongest-performing regimen for functional outcomes at six months across all injections studied. That finding speaks less to HA as a standalone option and more to its possible role as a scaffold alongside PRP — a separate clinical question from whether HA alone merits recommending.

Where does this leave the picture? The guideline caution reflects genuine limitations in the evidence, not a finding that HA is ineffective. For patients in the moderate-grade range for whom corticosteroid has already provided only short-term relief, a high-molecular-weight HA preparation is a reasonable option to raise in a specialist discussion. Patient selection and formulation choice appear to matter; a blanket position in either direction is difficult to sustain from the published data.

PRP for hip OA: a different evidence picture than the knee

PRP has accumulated a strong evidence base for knee osteoarthritis — but that evidence does not carry over to the hip as directly as many patients assume.

For the knee, systematic reviews consistently show PRP outperforming hyaluronic acid in both pain and function. The hip tells a different story. A 2024 scoping review by Tanguilig and colleagues identified two separate systematic reviews of randomised controlled trials comparing PRP with HA for hip OA, both of which found no significant difference in clinical outcomes between the groups at final follow-up. The hip joint's anatomy, biology, and mechanical environment differ enough from the knee that results cannot be assumed equivalent.

Who is most likely to benefit from PRP in the hip? Published data points towards younger patients at early-to-moderate OA grade, where less cartilage degeneration may allow growth-factor signalling to exert a meaningful effect on the synovial environment. As structural damage advances, that window appears to narrow. On dosing, preclinical in-vivo evidence suggests three intra-articular injections produce better synovial inflammation reduction and more durable results than a single dose. Leukocyte-rich formulations are associated with a higher risk of short-term post-injection pain and swelling — a practical consideration when discussing the protocol with patients.

One finding from a 2025 systematic review and meta-analysis (190 patients across two RCTs and one cohort study) is worth flagging clearly: adding HA to PRP for hip OA was associated with significantly worse pain scores at both 3 and 12 months compared with PRP alone, with no functional advantage from the combination. The mechanism is not fully established, but the growth-factor environment may be disrupted rather than enhanced by the HA addition. Where PRP is chosen, monotherapy appears preferable on current evidence.

A practical consideration: PRP is classified as experimental by most UK insurers and is typically an out-of-pocket expense — a factor that warrants discussion early in the treatment planning conversation.

Emerging orthobiologics: MSC and BMAC

Mesenchymal stem cells (MSC) and bone marrow aspirate concentrate (BMAC) sit at a different point on the biological spectrum from PRP. Rather than delivering growth factors to modulate the synovial environment, these therapies aim to introduce progenitor cells that are capable of anti-inflammatory paracrine signalling and, in principle, of contributing to cartilage matrix support. That mechanistic distinction is clinically relevant: the target is not symptom management in the way corticosteroids or HA work, but a potential degree of tissue-level influence — which is precisely what makes the evidence gap more consequential.

In practice, clinical trial data for MSC and BMAC in hip OA remain conflicting, and a 2022 review of intra-articular injection options for the hip concluded that neither has yet produced consistent clinical proof of benefit. No guidelines currently recommend them as part of routine care. These options tend to be discussed in the context of specialist assessment for patients who have not achieved sufficient relief from conventional injection pathways and are seeking to delay arthroplasty — a specific and relatively narrow clinical situation rather than an early-stage consideration.

Comparing options and what to weigh at your stage

The choice between these options is rarely binary. A specialist weighs OA grade, age, distance from arthroplasty, prior treatment response, and the patient's own goals simultaneously — which is why no algorithm replaces an individual assessment.

For someone needing fast, reliable short-term relief — to manage a flare, enable physiotherapy, or bridge to a planned procedure — corticosteroids remain the evidence-supported first choice. The 2024 Bayesian network meta-analysis of 16 RCTs (1,735 participants) gives that recommendation its clearest quantitative footing: significant superiority over placebo at three months for both pain and function.

For a younger patient at early-to-moderate grade who is not yet approaching arthroplasty, HA or PRP monotherapy represent reasonable alternatives at the six-month horizon — provided the evidence limitations are discussed honestly before the decision, including the fact that neither has demonstrated consistent superiority over placebo in this specific joint with the same trial volume as corticosteroids.

The placebo-response finding deserves a different framing at this stage than a trial-design footnote. It matters practically when patients evaluate their own outcomes. Feeling better after an injection does not, on its own, confirm that the pharmacological component was responsible. Tracking a structured outcome measure from a pre-injection baseline makes that question answerable; without one, response attribution remains uncertain — and so does the case for repeating the same treatment.

The thread running through all three modalities is that none modifies the underlying disease. The practical goal — extending comfortable, functional life in the joint before arthroplasty becomes necessary — is best served by well-timed selection and realistic milestones, not by identifying a universally superior option that the current evidence has not produced.